Drug
poly(I).poly(c12,U) clinical trials
Also written Ampligen, Rintatolimod and Atvogen.
- studies test it
- 18
- open now
- 0
- in phase 3
- 1
- first study started
- 1998
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2019 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2001 | 2 |
| 2011 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 12
- Phase 3
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 12
Roswell Park Cancer Institute (5) · AIM ImmunoTech Inc. (5) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Joachim Aerts, MD PhD (1) · Robert Edwards (1) · University of Washington (1) · HEM Research (1) · Abramson Cancer Center at Penn Medicine (1)
Often tested with
Tested in the same studies.
Interferon alpha-2 (4) · Celecoxib (3) · Pembrolizumab (2) · Durvalumab (1) · Aspirin (1) · Cisplatin (1) · Cyclophosphamide (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses poly(I).poly(c12,U) is read from its arms, and is right about nine times in ten.
Testing it · 18
- Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy EfficacyActive, not recruitingPhase 1/2Joachim Aerts, MD PhDNCT05927142Written as Rintatolimod
- Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPCSuspendedPhase 2AIM ImmunoTech Inc.NCT05494697Written as Rintatolimod
- Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before SurgeryActive, not recruitingPhase 2Roswell Park Cancer InstituteNCT03899987Written as Rintatolimod
- Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory MelanomaTerminatedPhase 2Roswell Park Cancer InstituteNCT04093323Written as Rintatolimod
- Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerActive, not recruitingPhase 1/2Robert EdwardsNCT03734692Written as Rintatolimod
- Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID ConditionsCompletedPhase 2AIM ImmunoTech Inc.NCT05592418Written as Rintatolimod
- Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast CancerCompletedPhase 1Roswell Park Cancer InstituteNCT04081389Written as Rintatolimod
- Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the LiverCompletedPhase 2Roswell Park Cancer InstituteNCT03403634Written as Rintatolimod
- Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerWithdrawnPhase 2Roswell Park Cancer InstituteNCT04119830Written as Rintatolimod
- A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedPhase 1/2Abramson Cancer Center at Penn MedicineNCT01312389Written as Ampligen
- A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARCCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000735Written as Ampligen
- A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected SubjectsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000713Written as Ampligen
- Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast CancerCompletedPhase 1/2University of WashingtonNCT01355393Written as rintatolimod
- The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue SyndromeCompletedPhase 3AIM ImmunoTech Inc.NCT00215800Written as Ampligen
- The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAARTCompletedPhase 2AIM ImmunoTech Inc.NCT00035893Written as poly I-poly C12U
- Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAARTTerminatedPhase 2AIM ImmunoTech Inc.NCT00035581Written as poly I-poly C12U
- A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of InfectionCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00001000Written as Ampligen
- A Multicenter, Double-Blind, Controlled Study to Evaluate AmpligenCompletedNot applicableHEM ResearchNCT00002269Written as Ampligen
Given in every arm · 5 — poly(I).poly(c12,U) is usual care beside what is tested
- Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian CancerNot yet recruitingPhase 2Kalinski, Pawel, MD, PhDNCT07634094Written as Rintatolimod
- Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast CancerTerminatedPhase 1/2Roswell Park Cancer InstituteNCT05756166Written as Rintatolimod
- Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer PatientsTerminatedPhase 1/2Roswell Park Cancer InstituteNCT04379518Written as Rintatolimod
- Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerCompletedEarly Phase 1Roswell Park Cancer InstituteNCT03599453Written as Rintatolimod
- αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface MalignanciesCompletedPhase 1/2David BartlettNCT02151448Written as rintatolimod
Codes
What other systems call poly(I).poly(c12,U) · ClinicalTrials.gg INT003249
- MeSH (NLM) C047490poly(I).poly(c12,U)Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 94325AJ25NRINTATOLIMODConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C047490 | poly(I).poly(c12,U) | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 94325AJ25N | RINTATOLIMOD | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.